"Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases." Expert Opinion on Biological Therapy, 16(10), pp. 1311–1312
No takes yet. Share an insight, caveat, or question.
Gentileschi et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: